Company news

uniQure N.V. news in 2026

uniQure N.V.'s news releases, calls and decks from 2026, newest first.

View company

uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update

November 4, 2026

uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease

November 2, 2026

uniQure to Announce Third Quarter 2026 Financial Results

October 28, 2026

UniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression

September 29, 2026

UniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

September 2, 2026

UniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

July 29, 2026

UniQure to Announce Second Quarter 2026 Financial Results

July 22, 2026

UniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 25, 2026

UniQure Announces Pricing of Upsized $225 Million Public Offering

June 23, 2026

uniQure Announces Pricing of Upsized $225 Million Public Offering

June 23, 2026

uniQure Announces $150 Million Proposed Public Offering

June 22, 2026

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

June 19, 2026

UniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease

June 17, 2026

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

May 5, 2026

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease

April 30, 2026

uniQure to Announce First Quarter 2026 Financial Results

April 28, 2026

uniQure Announces 2025 Financial Results and Provides Recent Company Updates

March 2, 2026

uniQure to Announce 2025 Financial Results

February 23, 2026

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

February 6, 2026

uniQure Announces Type A Meeting Scheduled with FDA

January 9, 2026

Calls in 2026

Decks in 2026